The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.
 
Takashi ONDA
Honoraria - Chugai Pharma; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toyomi Satoh
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; GE Healthcare; Kaken Pharmaceutical; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Philips Healthcare; Shionogi; Tsumura & Co.
 
Toshiaki Saito
Honoraria - Chugai Pharma; Eisai; Hisamitsu Pharmaceutical; Kaken Pharmaceutical; Nippon Kayaku; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Kasamatsu
No Relationships to Disclose
 
Toru Nakanishi
No Relationships to Disclose
 
Kazuhiro Takehara
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Nippon Kayaku; Taiho Pharmaceutical
 
Kenichi Miyamoto
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma
 
Aikou Okamoto
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Kissei Pharmaceutical (Inst); Meiji Holdings (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Pfizer (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Kimio Ushijima
Honoraria - Chugai Pharma
Research Funding - Kaken Pharmaceutical (Inst); Takeda (Inst); Tsumura & Co. (Inst)
 
Hiroaki Kobayashi
No Relationships to Disclose
 
Kei Kawana
Speakers' Bureau - Chugai Pharma; Kaken Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); MSD (Inst)
 
Harushige Yokota
Honoraria - Chugai Pharma; Kaken Pharmaceutical; MSD
Research Funding - Pfizer (Inst); Zeria Pharmaceutical (Inst)
 
Masashi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Kohei Omatsu
No Relationships to Disclose
 
Yoh Watanabe
No Relationships to Disclose
 
Kaichiro Yamamoto
Honoraria - Bayer
 
Nobuo Yaegashi
No Relationships to Disclose
 
Toshiharu Kamura
Consulting or Advisory Role - BrightPath Biotheraputics
 
Hiroyuki Yoshikawa
Honoraria - Eisai; GlaxoSmithKline
Consulting or Advisory Role - GlaxoSmithKline; MSD; Ono Pharmaceutical; Taiho Pharmaceutical